In recent years, the government has significantly increased its financial commitment to treating rare diseases, marking a substantial shift in healthcare policy since 2012. According to available data, the state allocated 130 million dinars in 2012 specifically for this purpose. This initial allocation was a significant step as it represented the first time such funds were set aside in the national budget for addressing rare diseases. Over the following years, these allocations have grown dramatically, reflecting a long-term strategy aimed at improving access to treatment for individuals affected by these conditions.
From 2013 up to 2026, the total amount allocated by the government reached 51.35 billion dinars. This figure represents a staggering increase compared to the initial sum from 2012, highlighting the government's growing emphasis on supporting patients with rare diseases. The expansion of funding has been accompanied by an increase in both the number of patients receiving treatment and the variety of rare diseases being addressed. In 2012, there were just eight patients benefiting from this funding, but by 2026, that number had risen to over 1,070. Additionally, the range of rare diseases covered expanded from two types in 2012 to 44 distinct varieties by 2026.
The funding for treating rare diseases does not solely come from the national budget. It also includes contributions from the Republic Fund for Health Insurance (RFZO), which provides medications listed under its drug list and purchases drugs directly from hospitals. When considering all sources of funding—both from the budget and through RFZO—the total amount allocated for treating rare diseases in 2025 exceeded 20 billion dinars. This figure is approximately ten times higher than the amount allocated in 2012, underscoring the comprehensive approach taken to ensure adequate resources for managing these complex health issues.
Specifically, the funds designated for children suffering from rare diseases have seen a notable rise. In 2012, the allocation stood at 130 million dinars, while between 2013 and 2026, the total amounted to 26.1 billion dinars. This increase reflects a targeted effort to support younger patients who often require specialized care and treatment regimens tailored to their unique medical needs.
When examining the broader picture, the overall funds allocated for treating rare diseases among both adults and children from 2012 to 2026 totaled 51.35 billion dinars. This encompasses all financial commitments made during this period, illustrating the sustained investment in addressing rare diseases. Prior to 2012, there were no specific allocations in the budget for treating rare diseases, making the year 2012 a pivotal moment in the country’s healthcare history regarding this issue.
The evolution of funding for rare disease treatments has brought about significant changes in patient care and accessibility to essential medicines. With more resources available, healthcare providers can offer better diagnostic tools, personalized treatment plans, and improved management strategies for patients dealing with rare conditions. These developments have contributed to a marked improvement in the quality of life for many individuals affected by rare diseases, allowing them to receive timely and appropriate medical attention that was previously limited due to insufficient funding and awareness.
2 reports
KurirParty-alignedCenterFactual 95Objective 857 days agoThe article reports on the significant increase in funding allocated by the state for the treatment of rare diseases in Serbia from 2012 to 2026. In 2012, 130 million dinars were allocated, which increased to over 10.2 billion dinars in 2026—a 78-fold increase. Between 2013 and 2026, a total of 51.35 billion dinars was allocated for this purpose. The number of patients treated with these funds rose from 8 in 2012 to 1,070 in 2026, while the number of recognized rare diseases increased from 2 to 44. Funding comes both from the budget and through the Republic Health Insurance Fund (RFZO), with over 20 billion dinars allocated in 2025 alone. The article highlights the expansion of support for both adults and children affected by rare diseases.
Bias read (Center): The article presents factual data on the growth of funding for rare disease treatments, emphasizing the scale of investment and outcomes without overtly praising or criticizing the government’s actions. It provides balanced figures and does not frame the issue in a partisan manner, maintaining a non
Why these scores (Factual 95 · Objective 85): This article mirrors the first in content and structure, providing the same numerical data and contextual information. It maintains consistency with the cross-source consensus but also has a similar tone that leans slightly towards highlighting achievements rather than presenting a neutral analysis.
Večernje novostiParty-alignedCenterFactual 95Objective 857 days agoThe article reports on the increased funding allocated by the Serbian government for the treatment of rare diseases since 2012. It highlights that in 2012, 130 million dinars were initially set aside, which has grown significantly over time. By 2026, total funds allocated for treating rare diseases reached 51.35 billion dinars, representing a 78-fold increase compared to 2012. The number of patients treated using these funds rose from 8 in 2012 to 1,070 by 2026, while the number of recognized rare diseases increased from 2 to 44. The funding includes both budget allocations and support through the Republic Health Insurance Fund (RFZO).
Bias read (Center): The article presents factual data on government spending increases for rare disease treatments without overtly praising or criticizing the policy. While the growth in funding is emphasized, there is no clear ideological leaning in the framing of the information. The focus remains on statistical and財
Why these scores (Factual 95 · Objective 85): The article presents detailed figures on funding for rare disease treatment from 2012 to 2026, aligning with cross-source consensus. It includes specific numbers like 51.35 billion dinars and 1070 patients, which are consistent with other reports. The tone is informative but slightly promotional, su
★
Keep the news honest.
ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €5/month.
Become a Supporter
Serbia
